BioSpace News Archive

ImmunoGen, Inc. announced that full data and additional exploratory analyses from the Phase 3 FORWARD I study evaluating mirvetuximab soravtansine compared to chemotherapy in women with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) Congress to be held from September 27 to October 1, 2019 in Barcelona, Spain.

Centene Corporation and Feeding America® announced the launch of the ‘Food for Today and Food for Tomorrow’ resource development initiative, a program that will equip network food banks and Centene health plans with best practice guidelines for meeting the needs of individuals experiencing food insecurity.

Leap Therapeutics, Inc. announced an oral and poster presentation of updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its anti-Dickkopf-1 antibody, as both a monotherapy and in combination with paclitaxel chemotherapy in patients with advanced gynecological malignancies will be presented at the 2019 International Gynecologic Cancer Society Annual Global Meeting taking place September 19-21, 2019 in Rio de Janeiro, Brazil.

Regeneron Pharmaceuticals, Inc. announced that the company was added to the Dow Jones Sustainability World Index for the first time.

Concert Pharmaceuticals, Inc. announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata.

Medicenna Therapeutics Corp. announced that it will present an update on the lead candidate from its IL-2 superkine platform, MDNA19, at the International Cancer Immunotherapy Conference to be held from September 25-28, 2019 in Paris, France.

TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) (“TerrAscend” or “the Company”), the first and only global cannabis company licensed for sales in Canada, the US, and the EU, today announced it has closed on its previously announced acquisition of Pennsylvania-based Ilera Healthcare, one of five permitted vertically-integrated cannabis cultivator, processor, and dispensary operators in the state.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will present at the 2019 Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019 at 3:00 p.m. Eastern Time in New York, NY.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the company has completed its site initiation visit for the first site to be included in its upcoming keloid scar proof-of-concept trial.

The U.S. Food and Drug Administration (FDA) has named AnaBios the recipient of a grant to further develop its unique drug discovery platform utilizing muscle cells from the human heart (cardiomyocytes).